Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court Upholds Norvasc Patent

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex will be prohibited from launching a generic of amlodipine until September 2007, according to a Jan. 18 ruling out of Chicago federal court

You may also be interested in...



Pfizer’s Norvasc Does Not Infringe Synthon Patent, Court Finds

The company’s revenues stemming from its blockbuster hypertension treatment remain safe after Synthon had challenged its manufacturing process.

Pfizer’s Norvasc Does Not Infringe Synthon Patent, Court Finds

The company’s revenues stemming from its blockbuster hypertension treatment remain safe after Synthon had challenged its manufacturing process.

Mylan Granted 180-Day Exclusivity On Norvasc

Mylan holds 180-day exclusivity on all three doses of Pfizer's Norvasc following FDA's confirmation that the generic firm was first-to-file on the 2.5 mg, 5 mg and 10 mg amlodipine doses, the company announced Oct. 4

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel